Abstract
A nonvalvular atrial fibrillation (NVAF) is the most important risk factor in patients with cardioembolic stroke, however the antithrombotic strategy for this arrhythmia is not sufficient in Japan. Because of the high bleeding complication, one of the major impediments in Japanese patients is to indicate anticoagulation.
The penetration rate of the treatment is still low. To avoid the hemorrhagic complication, it is very important to include and limit the cases with higher risk for thrombosis. We put our hopes on enhanced multi-slice chest computed tomography and several hemostatic molecular markers to evaluate the embolic risk. In the case of secondary prevention therapy, custom-tailored anticoagulation, and careful control of this is a special concern. The occurrence of cardioembolic stroke can be reduced to one-half, if we perform the ideal prevention strategy for NVAF.
